Levothyroxine chemical structure
Find information on thousands of medical conditions and prescription drugs.

Levoxyl


Levothyroxine, also known as L-thyroxine, synthetic T4 or simply 3,5,3',5'-tetraiodo-L-thyronine, is a synthetic form of thyroxine (thyroid hormone). As the hormone is chemically in the L-form (instead of D, see chirality), it is metabolised much slower than physiological thyroid hormone, which has a shorter half-life. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

The EU has recently standardised the use of the name "levothyroxine" for the drug. Common brand names include "Thyrax", "Euthyrox", "Levaxin" and "Eltroxin" in Europe, and "Levoxyl" and "Synthroid" in the US.

This medicine is usually given to patients with thyroid problems. These many problems can affect the patient's (if he/she is a child/teenager) growth and/or weight.

Read more at Wikipedia.org


[List your site here Free!]


Levothyroxine and FDA bioequivalence ratings
From Journal of Family Practice, 2/1/05 by Gary N. Fox

TO THE EDITOR:

A Clinical Inquiry published in the November issue of the journal ("How should thyroid replacement be initiated?," J Fam Pract 2004; 53:925) discussed initiation of thyroid hormone replacement therapy. The authors and commentator do not specifically state that levothyroxine sodium preparations "usually are administered orally on an empty stomach, preferably one-half to one hour before breakfast or the first food of the day." (1)

Additionally, there is information about the Food and Drug Administration's (FDA) bioequivalence ratings that became available after the authors had submitted. The October 2004 Supplement to the FDA "Orange Book" now lists genetic equivalents to each brand-name levothyroxine product. (2)

FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products:

"Levothyroxine Sodium (Mylan) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens) tablets.

"Levo-T (Alara) and Levothyroxine Sodium (Mylan) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott) tablets.

"Levo-T (Alara), Unithroid (Jerome Stevens) and Levothyroxine Sodium (Mylan) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King/Jones Pharma) tablets."

Novothyrox (Genpharm), Thyro-Tabs (Lloyd), and Levolet (Vintage) are listed as requiting further investigation to establish therapeutic equivalence to other levothyroxine products.

Except for these latter 3, if one believes that equivalents of equivalents are equivalent, as illustrated in the Table, all the major levothyroxine preparations appear equivalent.

REFERENCES

(1.) AHFS Drug Information. Levothyroxine Sodium. (68:36.04 Thyroid Agents.) AHFS Drug Information (2004). Via Stat!Ref online. Available at: http://online.statref.com/. Accessed on November 23, 2004.

(2.) Food and Drug Administration, Center for Drug Evaluation and Research. Approved Drug Products with Therapeutic Equivalence Evaluations. 24th ed. Cumulative Supplement 10. Prepared By Office of Pharmaceutical Science, Office of Generic Drugs, Center for Drug Evaluation and Research, FDA. October 2004. Available at: www.fda.gov/cder/orange/supplement/cspreface.htm#1.4. Accessed on November 23, 2004.

Gary N. Fox, MD, Mercy Health Partners Family Practice Residency, Toledo, Ohio

COPYRIGHT 2005 Dowden Health Media, Inc.
COPYRIGHT 2005 Gale Group

Return to Levoxyl
Home Contact Resources Exchange Links ebay